A Study To Evaluate The Dose Response And Safety Of PHA-794428 In Adults With Growth Hormone Deficiency
The purpose of this study is to explore the safety, toleration and dose response of PHA-794428 after multiple weekly injections in male and female growth hormone deficient patients.
|Study Design:||Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Primary Purpose: Treatment
|Official Title:||A Double Blind Parallel Group Randomised Multiple Dose Study To Evaluate The Pharmacodynamic Response And Safety Of PHA-794428 In Adult Growth Hormone Deficient Patients|
- Responder status at visits 9 (week 4) and 14 (week 7), where responder is defined as a patient who has achieved an IGF-1 level above the mid-point of the age-related normal range.
- Change in PD and glycemic control [ Time Frame: At weeks 4 and 7 ]
- Change in PK concentrations.
- ALT, AST greater than 3.0 times ULN at any visit
- Anti-hGH and anti PHA-794428 antibody production
- Change in body weight [ Time Frame: At week 4 and follow-up ]
- Injection site reactions
|Study Start Date:||July 2006|
|Study Completion Date:||December 2007|
|Primary Completion Date:||December 2007 (Final data collection date for primary outcome measure)|
The study terminated on 10-Dec-2007. Pfizer's decision to terminate the program was due to cases of injection-site lipoatrophy that were reported in the clinical Phase 2 studies after a single injection of PHA 794428.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00308464
Show 35 Study Locations
|Study Director:||Pfizer CT.gov Call Center||Pfizer|